NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Cupid Share Price Rises 3% to ₹80.95 Amid Development Program Announcement

Market Capitalization: ₹10,622 Crore

On Tuesday, March 17, Cupid shares continued their upward trend, surging 3% to a high of ₹80.95 apiece. This marks the second consecutive day of gains for the small-cap stock.

Development Program Announcement

Cupid has announced the commencement of its development program for a nitrile (NBR) female contraceptive. The company aims to enter the currently single-supplier global nitrile female contraceptive market, which is estimated to be valued at approximately USD 770 million in 2024 and projected to exceed USD 1.2 billion by 2030.

Read also: SpaceX Seeks Record $75 Billion IPO, Potentially Positioning Elon Musk as the World's First Trillionaire

Strategic Branding Alignment

The company has also announced a strategic branding alignment centered on the proposition "Made in India" with "Japanese Quality", reinforcing its commitment to combining India's strong manufacturing capabilities with globally recognised standards of precision, reliability, and product excellence.

Market Opportunity

Cupid's entry into the nitrile female contraceptive segment represents a significant strategic opportunity, driven by several compelling factors, including supply diversification, a premium product segment, and technical and regulatory barriers to entry.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Share Price Trend

Cupid shares have staged a stellar rebound in April 2025 with a surge of 25%. The momentum further strengthened over the following eight months, resulting in a massive gain of 600%. However, profit booking dragged the stock lower by 22.60% in January, while in the following month it delivered a muted return of 1.5%. Nevertheless, the strong nine-month rally helped the stock gain 525% over the past year and a massive 3,168% over three years.

Trading Status

Cupid shares have been trading ex-bonus in the ratio of 4:1 since March 9, 2026.

Investor Takeaway

Investors should consider Cupid's potential for long-term growth in the expanding female contraceptive market.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.